MSN rolls out black fungus drug in India | Hyderabad News | Sidnaz Blog

Rate this post

[ad_1]

Amid an alarming rise in the number of Covid-19 patients suffering from mucormycosis (more commonly referred to as black fungus), Hyderabad-based pharma player MSN Laboratories (MSN) said it has rolled out anti-fungal drug posaconazole in tablet and injectable form in the country.

HYDERABAD: Amid an alarming rise in the number of Covid-19 patients suffering from mucormycosis (more commonly referred to as black fungus), Hyderabad-based pharma player MSN Laboratories (MSN) said it has rolled out anti-fungal drug posaconazole in tablet and injectable form in the country.
The triazole anti-fungal drug, which has been launched under the PosaOne brand by MSN, has been priced at Rs 600 for each 100mg delayed release tablet and Rs 8,500 for the 300mg injection each, the company said on Friday.
The company said it has developed the active pharmaceutical ingredient (API) as well as the formulation of PosaOne at its in-house R&D and manufacturing units.
Pointing out that many patients recovering from Covid-19 have been detected with the rare and deadly fungal infection, the company said with the mortality rates on the rise, accessibility of anti-fungal medication is an unmet deficit in these testing times, which the company is looking to address.
The drug was recently approved by the Drug Controller General of India (DCGI) and matches up to international quality standards, the company said.
MSN’s portfolio of Covid-19 treatment drugs includes favipiravir in 200mg, 400mg and 800mg tablet form and baricitinib, for which it recently entered into a royalty-free, non-exclusive voluntary licencing agreement with Eli Lilly.
In fact, MSN rolled out the world’s most affordable favipiravir under the Favilow brand at Rs 33 per tablet of 200mg in August last year.

FacebookTwitterLinkedinEMail

[ad_2]

Source link

Author: royalstylewebsitecreations